ReviewNature clinical practice. Oncology2005
Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies.
Review in Nature clinical practice. Oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 64 citations in OpenAlex.
- Epstein-Barr virus mRNA vaccine synergizes with NK cells to enhance nasopharyngeal carcinoma eradication in humanized mice.Molecular therapy. Oncology · 2025Article
- A lipid-based LMP2-mRNA vaccine to treat nasopharyngeal carcinoma.Nano research · 2023Article
- EBV protection- and susceptibility-related HLA alleles and EBV status in the Chinese population: A single-center study.Immunity, inflammation and disease · 2022Article
- A practical method to screen and identify functioning biomarkers in nasopharyngeal carcinoma.Scientific reports · 2021Article
- EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.Blood · 2021Article
- Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.BMC cancer · 2017Article
- Identifying novel genes and chemicals related to nasopharyngeal cancer in a heterogeneous network.Scientific reports · 2016Article
- The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.Clinical and experimental immunology · 2016Article
- Association between interferon gamma 13-CA-repeats polymorphism and metastasis of nasopharyngeal carcinoma in a population of Northern China.International journal of clinical and experimental pathology · 2015Article
- Article
- mRNA Structural constraints on EBNA1 synthesis impact on in vivo antigen presentation and early priming of CD8+ T cells.PLoS pathogens · 2014Article
- Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma.Therapeutics and clinical risk management · 2014Review
- The Epstein-Barr virus microRNA BART11-5p targets the early B-cell transcription factor EBF1.American journal of blood research · 2013Article
- T-cell therapy in the treatment of post-transplant lymphoproliferative disease.Nature reviews. Clinical oncology · 2012Review
- Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly expresses EBNA3A with conserved CD8 T-cell epitopes.American journal of blood research · 2011Article
- Immunotherapy for epstein-barr virus-related lymphomas.Mediterranean journal of hematology and infectious diseases · 2009Article
- The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1-mediated suppression.Journal of virology · 2009Article
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.Nature medicine · 2008Article
- Tumor-specific immune responses.Seminars in immunology · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Epstein-Barr virus (EBV) is uniquely associated with a broad range of human malignancies. In spite of their diverse cellular origin, most of these malignancies share common features, including the expression of either some or all of the EBV latent proteins, which can be potentially exploited for immune-based therapies. Here we discuss new and emerging strategies to manipulate the immune response to specifically boost T-cell immunity towards viral proteins that are expressed in EBV-associated malignancies. These strategies are used either alone or as an adjuvant therapy in combination with chemotherapy and/or monoclonal antibodies. Overall, this strategy may serve as a new paradigm for the successful multi-modality treatment of malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.